Human cell line derived from Wilms' tumor. Expressing CA125 and TPA.
Comment from the depositor
Terms and conditions
Need an approval of the approver. Academic basic research purpose only (excluding any type of commercial use, i.e., commercializing not only HFWT cells but also all the HFWT-originated commercially useful materials and methods such as the cellular components, products, genes, their derivatives, application methods, and the like.) .
Remarks
approver's address
×
English
Address
Cell-Medicine, Inc. Headquater 2-1-6 Sengen, Tsukuba, Ibaraki 305-0047 Japan
Dr.OHNO Tadao
Fax. +81-29-828-5592
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
2719
Harada, Hideki, Saijo, Kaoru, Ishiwata, Isamu, Ohno, Tadao
A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.Hum Cell
2004
17:43-8
PubMed ID: 15369136
DOI: 10.1111/j.1749-0774.2004.tb00019.x
859
Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T.
A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cellsExp Hematol
2004
32(7):614-21
PubMed ID: 15246157
DOI: 10.1016/j.exphem.2004.03.011
858
Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H.
Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancerBJU Int
2003
92(9):1009-15
PubMed ID: 14632866
DOI: 10.1111/j.1464-410x.2003.04509.x
861
Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I, Ohno T.
Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWTJpn J Cancer Res
2002
93(3):313-9
PubMed ID: 11927014
DOI: 10.1111/j.1349-7006.2002.tb02174.x
1525
Ishiwata I, Ono I, Ishiwata C, Soma M, Nakaguchi T, Ohara K, Hirano M, Ishikawa H
Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.Exp Pathol
1991
41:1-9
PubMed ID: 1850701
DOI: 10.1016/s0232-1513(11)80040-x
19735
Zhu S, Zhou R, Tang X, Fu W, Jia W.
Hypoxia/inflammation-induced upregulation of HIF-1α and C/EBPβ promotes nephroblastoma cell EMT by improving HOXA11-AS transcriptionHeliyon
2024
10(6):e27654
PubMed ID: 38524550
DOI: 10.1016/j.heliyon.2024.e27654
20687
Zhu Q, Zhan D, Yang Y, Chong Y, Xue H, Zhu P.
LINC00173 Promotes Wilms' Tumor Progression Through MGAT1-mediated MUC3A N-glycosylation.Cell Cycle
2022
PubMed ID: 35491865
DOI: 10.1080/15384101.2022.2070399
20062
Zhu S, Zhang J, Gao X, Tang X, Cui Y, Li D, Jia W.
Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2.J Cell Physiol
2021
PubMed ID: 33438217
DOI: 10.1002/jcp.30259
12051
Zhu S, Zhang J, Cui Y, Tang X, Gao X, Li D, Jia W.
Long non-coding RNA HOXA11-AS upregulates Cyclin D2 to inhibit apoptosis and promote cell cycle progression in nephroblastoma by recruiting forkhead box P2.Am J Cancer Res
2020
PubMed ID: 32064168
18270
Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y.
Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumorPediatr Blood Cancer
2012
59(3):499-505
PubMed ID: 22457227
DOI: 10.1002/pbc.24093